INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV) Files An 8-K Regulation FD Disclosure
Item 8.01. Regulation FD Disclosure.

On July31, 2017,InVivo Therapeutics Holdings Corp. (the “Company”) posted an updated corporate presentation in the “Investor Relations” section of its website at www.invivotherapeutics.com.

Item 8.01. Other Events.

On July31, 2017, the Company issued a press release announcing certain updates on the INSPIRE Study, including new patient conversions and a temporary enrollment halt. A copy of the press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 8.01. Financial Statements and Exhibits.

(d)Exhibits

The Exhibitto this Current Report on Form8-K is listed in the ExhibitIndex attached hereto.


INVIVO THERAPEUTICS HOLDINGS CORP. Exhibit
EX-99.1 2 a17-18595_3ex99d1.htm EX-99.1 Exhibit 99.1     CONTACT: Heather Hamel (617) 863-5530 Investor Relations [email protected]   InVivo Therapeutics Announces Updates on the INSPIRE Study   – Announces Two New Patient Conversions –   – Implements Temporary Enrollment Halt –   CAMBRIDGE,…
To view the full exhibit click here

About INVIVO THERAPEUTICS HOLDINGS CORP. (NASDAQ:NVIV)

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.